ArticleAnnals of medicine and surgery (2012)2025
To develop prognostic markers related to drug resistance in pancreatic cancer patients based on multiple machine learning methods.
Article in Annals of medicine and surgery (2012), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to identify novel prognostic biomarkers and therapeutic strategies by focusing on drug resistance-related phenotypes. We integrated multi-omics data from various databases encompassing sequencing, clinical information, resistance-related gene sets, and genomic alteration data. ssGSEA was employed to calculate resistance scores for individual samples, which were subsequently applied in survival analysis. Furthermore, we utilized machine learning algorithms to develop a robust prognostic model validated across multiple independent datasets. Our findings revealed 12 genes consistently linked to pancreatic adenocarcinoma (PAAD) prognosis in diverse datasets. Pathway enrichment analysis indicated that the high-risk group was enriched in pathways associated with systemic lupus erythematosus and the cell cycle, whereas the low-risk group showed significant enrichment in neuroactive ligand-receptor interaction pathways. Additionally, immune cell infiltration analysis exhibited substantial differences between risk groups, with the high-risk cohort presenting lower levels of activated CD8+ T cells but higher levels of regulatory T cells. The random survival forest model demonstrated superior predictive performance, achieving a concordance index of 0.634 and time-dependent receiver operating characteristic area under the curve values of 0.973, 0.978, and 0.996 at 1, 2, and 3 years, respectively. In conclusion, this study identifies 12 critical drug resistance genes in PAAD and highlights the associated immune differences in patient risk, paving the way for targeted immunotherapy research to improve therapeutic strategies against this formidable disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.